How do you approach using CD 19/20 levels to redose Rituximab for ANCA associated vasculitis?

In the MAINRITSAN 2 trial, a tailored rituximab regimen adapted to ANCA-positivity or ANCA-titre change and/or circulating CD19+ B cell repopulation was compared with fixed-schedule rituximab infusions.

There was no significant difference in relapse rates between the fixed-dose and tailored-dose arms...

CD 19+B cell latency may serve as a surrogate for individualized therapy with Rituxan.